RecruitingPhase 3NCT03925662
Mebendazole as Adjuvant Treatment for Colon Cancer
Clinical Study Evaluating Mebendazole as Adjuvant Therapy in Patients With Colorectal Cancer
Sponsor
Sherief Abd-Elsalam
Enrollment
40 participants
Start Date
Apr 1, 2019
Study Type
INTERVENTIONAL
Conditions
Summary
mebendazole treating colon cancer
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- Colorectal cancer stage 4.
Exclusion Criteria3
- Agranulocytosis
- Pregnancy
- Allergy to mebendazole.
Interventions
DRUGFolfox with avastin
Folfox with avastin only
DRUGMebendazole
Folfox with avastin with mebendazole
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03925662
Related Trials
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
NCT0546403035 locations
A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer
NCT070717141 location
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
NCT069922589 locations
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
NCT0701157614 locations
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
NCT0697316127 locations